市场调查报告书
商品编码
1492567
全球Fentanyl市场、按产品类型、应用和分销管道分類的市场 - 2024-2030 年全球预测Fentanyl Market by Product Type (Injectables, Lozenges & Tablets, Nasal Sprays), Application (Anesthesia, Chronic Pain Management, Surgical Pain Management), Distribution Channel - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年Fentanyl市场规模为26.4亿美元,预计2024年将达27.7亿美元,2030年将达到36.4亿美元,复合年增长率为4.65%。
Fentanyl用于治疗与手术或癌症等慢性疾病相关的严重疼痛,通常用于安宁疗护和麻醉。需要手术的慢性疾病的日益流行导致对包括Fentanyl在内的有效止痛药物的需求。医疗实践和麻醉技术的创新导致了客製化疼痛管理方案的开发,其中包括Fentanyl等鸦片类药物,因为它们的有效性。新兴市场医疗保健设施和准入的改善也推动了对强效止痛药的需求,从而提振了Fentanyl市场。然而,滥用和依赖风险的增加导致对阿片类药物的处方和分销的监管更加严格,从而影响了Fentanyl市场。来自非鸦片类镇痛药的竞争加剧可能会对市场扩张构成挑战。此外,滥用威慑配方的创新可以减少滥用的可能性并提高合法用户的安全性,可以扩大市场范围。副作用减少的Fentanyl类似物的合成可能会在市场上提供巨大的成长潜力。
主要市场统计 | |
---|---|
基准年[2023] | 26.4亿美元 |
预测年份 [2024] | 27.7亿美元 |
预测年份 [2030] | 36.4亿美元 |
复合年增长率(%) | 4.65% |
区域洞察
在美洲,特别是在美国和加拿大,对Fentanyl的需求主要由癌症治疗和手术疼痛管理等医疗部门推动。美洲地区的客户购买行为表明他们倾向于处方和受控使用,并有强有力的法律规范来管理Fentanyl等鸦片类药物的配发。欧洲,特别是欧盟内部,在监管机构严格指导方针的指导下,对Fentanyl的使用采取了谨慎的态度。欧洲、中东和非洲地区的研究重点是最大限度地减少滥用可能性和副作用的输送系统,从而推动该地区的市场扩张。在中东和非洲地区,受沙乌地阿拉伯和阿拉伯联合大公国医疗保健系统改善的影响,包括Fentanyl在内的鸦片类药物的医疗使用正在增加。在非洲,这些强效鸦片类药物的取得和需求有限,这主要是由于医疗保健投资较低和法规环境充满挑战。从产品类型、用途和分销管道来看,中国是亚太地区医药Fentanyl消费和生产的重要国家。日本由于其严格的药品监管和人口老化,对医疗处方Fentanyl的需求表现出较高的医疗标准,从产品类型、应用和分销管道来看,特别是在疼痛管理方面。印度正在逐步增加先进医用止痛药的适应症,并制定了严格的指导方针,以避免药物滥用和依赖。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在Fentanyl市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对Fentanyl市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对Fentanyl市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[186 Pages Report] The Fentanyl Market size was estimated at USD 2.64 billion in 2023 and expected to reach USD 2.77 billion in 2024, at a CAGR 4.65% to reach USD 3.64 billion by 2030.
Fentanyl is prescribed for severe pain typically associated with surgical procedures and chronic conditions such as cancer and is often used in both palliative care and anesthesia. The rising prevalence of chronic diseases requiring surgeries contributes to the demand for effective pain management drugs, including fentanyl. Innovations in medical practices and anesthetic techniques have led to tailored pain management protocols, which include opioids such as fentanyl due to their efficacy. Improved healthcare facilities and access in emerging markets also drive the demand for potent analgesics, thereby boosting the fentanyl market. However, the high risk of misuse and dependency has led to stringent controls on opioid prescription and distribution, impacting fentanyl's market. Increasing competition from non-opioid pain relievers may create challenges for market expansion. Moreover, the innovation of abuse-deterrent formulations that reduce the potential for abuse and improve the safety of legitimate users may expand market scope. Synthesis of fentanyl analogs with reduced side effects may create significant growth potential in the market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.64 billion |
Estimated Year [2024] | USD 2.77 billion |
Forecast Year [2030] | USD 3.64 billion |
CAGR (%) | 4.65% |
Regional Insights
In the Americas region, particularly in the United States and Canada, the demand for fentanyl has been significantly influenced by the medical sector, primarily for pain management in cancer treatments and surgeries. The customer purchasing behavior in the Americas region shows a preference for prescribed controlled usage, driven by a robust regulatory framework that governs the dispensation of opioid medications such as fentanyl. In Europe, particularly within the EU, there's a cautious approach toward fentanyl use, guided by strict guidelines by regulatory authorities. Research in the EMEA region has focused on delivery systems that minimize abuse potential and side effects, driving the market expansion in the region. The Middle East and Africa regions show an increasing trend in the medical use of opioids, including fentanyl, influenced by improving healthcare systems in Saudi Arabia and the UAE. Africa has limited access to and demand for such strong opioids, primarily due to lower healthcare investment and stringent regulatory environments. In the Asia-Pacific region, China has been a significant country in the consumption and production of pharmaceutical fentanyl. Japan, with its strict drug control laws and an aging population, shows demand for medically prescribed fentanyl, particularly in pain management, derived from high healthcare standards. India is gradually increasing its adaptation of advanced medical pain relief and has established stringent guidelines to avoid drug abuse and dependency.
Market Insights
The market dynamics represent an ever-changing landscape of the Fentanyl Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Fentanyl Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Fentanyl Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Hikma Pharmaceuticals Introduces New Fentanyl Citrate Injections for Advanced Pain Management in Clinical Settings
Hikma Pharmaceuticals PLC has expanded its product range in the United States with the introduction of Fentanyl Citrate Injection, USP. The fentanyl injections are primarily utilized for short-duration analgesic action during various phases of anesthesia, including premedication, induction, maintenance, and immediate postoperative recovery. This approval by the FDA, however, limits the marketing of this product exclusively to the United States, enhancing Hikma's portfolio and offering more options to healthcare facilities in managing critical pain effectively. [Published On: 2024-02-20]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Fentanyl Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Fentanyl Market, highlighting leading vendors and their innovative profiles. These include Biesterfeld AG, Cambrex Corporation, Daiichi Sankyo Company, Limited, Endo International PLC, Fresenius Kabi, Hikma Pharmaceuticals PLC, Janssen Pharmaceutica, Pfizer Inc., Prostrakan Pharmaceuticals by Kyowa Hakko Kirin Co. Ltd., SELLAS Life Sciences Group, Spectrum Chemical Mfg. Corp., Tofigh Daru, and Verve HumanCare Laboratories.
Market Segmentation & Coverage